Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic ...

Initial discussions about treatment, side effects and study results can help patients navigate through all aspects of a chronic myeloid leukemia diagnosis. The initial discussions with health care ...

Survey results suggest that chronic myeloid leukaemia (CML) patients using tyrosine kinase inhibitor (TKI) therapy have good adherence to treatment but might benefit from counselling regarding their ...

Lindsay A. Rein, MD, reviews exciting data presented at this year’s ASH meeting, focusing on chronic myeloid leukemia (CML) and the recent approval of asciminib, a novel agent for first-, second-, and ...

A study from a major cancer center collected data on 2857 patients with Ph+ CML, most of whom were White and middle-aged. Ten-year overall survival for patients with Ph+ CML treated since 2000 was ...

Chronic myeloid leukemia (CML) is a type of blood cancer. CML is Philadelphia chromosome-positive (Ph+) when pieces of chromosomes 9 and 22 break off and swap places. This creates a new abnormal ...